CAR-T 細胞與基因治療研發(fā)創(chuàng)新及生產(chǎn)工藝開發(fā)國際峰會2020 ( APRDL 2020 )
2020年10月15- 16日 | 上海浦東錦江湯臣洲際大酒店
會議日期：2020年10月15 -16日
會議地點：上海
往屆照片：photo.html
2019峰會視頻：q0872t52sr8.html
2018 峰會視頻：u0666uknzn3.html
Event Information/會議信息:
Event Name: Asia Pharma R&D Leaders Summit 2020
Event Date: Oct.15 (Thur.) to 16 (Fri.).2020
Event Venue: InterContinental Shanghai Pudong Hotel
Event Link:
www.aprdl2020.com
Expected Number of Speakers: 60-70
Expected Number of Attendees: 280-300
會議名稱: Asia Pharma R&D Leaders Summit 2020
會議時間: 2020年10月15-16日
會議地點: 上海浦東錦江湯臣洲際大酒店
會議網(wǎng)址: www.aprdl2020.com
預(yù)計演講嘉賓人數(shù):60-70
預(yù)計與會嘉賓人數(shù):280-300
2020 Seminar Main Discussions
Cell Therapy Bioprocessing and Commercialization Stream
細胞治療產(chǎn)品生產(chǎn)工藝開發(fā)及商業(yè)化進展
Oct.15 (Thur.) to 16 (Fri.).2020
Main Discussions/主要議題
- Regulatory and Commercialization Considerations for Cell Therapy Products Development in China
- Cell Therapy Manufacturing Commercialization in China - Strategy and Challenges
- Cell Therapy Bioprocessing, Key CMC Strategy and Quality Control Considerations
- Breakthrough Technologies Innovation
- Automated Manufacturing of Chimeric Antigen Receptor T Cells
- Disruptive GMP Manufacturing for “Off-The-Shelf” CAR-T Cell Therapy
- CAR-T 細胞治療產(chǎn)品在中國開發(fā)的法規(guī)和商業(yè)化進展
- 細胞治療產(chǎn)品在中國的商業(yè)化生產(chǎn)面臨的挑戰(zhàn)
- 細胞治療生產(chǎn)工藝技術(shù)創(chuàng)新與進展
- CAR-T細胞的自動化生產(chǎn)
- 革命性技術(shù)及創(chuàng)新平臺在細胞治療產(chǎn)品商業(yè)化過程中的應(yīng)用
- 現(xiàn)成通用的CAR-T細胞治療產(chǎn)品 在生產(chǎn)與質(zhì)量控制過程中面臨的挑戰(zhàn)和解決方案
CAR-TCR Clinical Research and Innovation Stream
CAR-TCR細胞治療產(chǎn)品臨床研究及開發(fā)策略
Oct.15 (Thur.) to 16 (Fri.).2020
Main Discussions/主要議題
- Surface Density of CAR Molecules Modulate the Kinetics of CAR-T Cells In Vivo
- Humanized Animal Model for CAT-T Cell Therapy Research
- Mechanisms & Clinical Study of CAR-NK Cell Drugs to Treat Solid Tumors
- Clinical Development of CAR T Cell Therapy and Next Generation
PD-1 Armored CAR-T Cells
- TCR-T Cell-based Immunotherapy for Solid Cancers
- Advancing Cancer Adoptive Immunotherapy with CRISPR/Cas9 Gene Edited T Cells
- Developing Allogeneic Cancer Immunotherapy with iPSC Technology
- 新一代抑制PD1的 “裝甲” CAR-T產(chǎn)品的臨床開發(fā)
- 將ARTEMISTM T 細胞 與TCR模擬抗體結(jié)合 治療實體瘤
- CRISPR/Cas9
基因編輯的T細胞過繼性免疫治療的應(yīng)用
- TCR-T 細胞療法在實體瘤臨床研究的應(yīng)用
- 現(xiàn)成通用的CAR-NK細胞產(chǎn)品治療實體瘤的機理及臨床進展
- 人源化動物模型在CAR-T細胞療法研究中的應(yīng)用
- 運用iPSC技術(shù)來開發(fā) 同種異體癌癥免疫療法
Bio-Pharmaceutical Acceleration Development Stream
生物制品的加速開發(fā)與合作
Oct.15 (Thur.) to 16 (Fri.).2020
Main Discussions / 主要議題
- Strengthening Collaboration for Next Generation Immuno-Oncology Drug Development
- Challenges and Opportunities of Global Bio-Therapeutic Industry
- Novel Business Partnership Model for Therapeutic Biologicals
Acceleration Development in China
- Integrated Global and Local Clinical Research Strategy to Advancing Immune Oncology in China
- Revolution in Future Cancer Immunotherapy
- Perceiving the Role and Importance of Asia & China for Global Drug Development
- The Drug Marketing Authorization Holder (MAH) System in China: CMO-MAH Integration Programs Collaboration
- 下一代免疫腫瘤藥品開發(fā)的創(chuàng)新合作模式
- 全球生物藥研發(fā)的挑戰(zhàn)與機會: 新時代新機遇新方向
- 治療性生物制品在中國的創(chuàng)新加速開發(fā)及合作模式
- 通過整合全球和中國的臨床研究策略來加速免疫腫瘤藥品的開發(fā)
- 未來癌癥免疫研究的變革
- 中國原創(chuàng)新藥的全球臨床開發(fā)的機遇與挑戰(zhàn)
- 生物藥創(chuàng)新趨勢, MAH制度, 生物醫(yī)藥合同外包現(xiàn)狀與趨勢
更多關(guān)于發(fā)言, 參會及贊助方案，請聯(lián)系：
聯(lián)系人：Kevin Tan
聯(lián)系電話：+86 21 6157 7321 / +86 1364 1961 545
Email:
kevin.tan@deliver-consulting.com
Organizing and Planning Committee | Asia Pharma R&D Leaders Summit 2020
Add: 26F, Infinitus Tower, No. 168, Hubin Road. Huangpu District, Shanghai, PR. China, 200021
